Influence of PI3K/AKT pathway on imatinib mesylate treatment outcome in chronic myeloid leukemia patients

被引：0
|
作者：
Banapuram, Swathi [1 ]
Gorre, Manjula [1 ]
Digumarti, Raghunadha Rao [2 ]
Satti, Vishnupriya [1 ]
Palle, Komaraiah [3 ]
Annamaneni, Sandhya [3 ,4 ]
机构：
[1] Osmania Univ, Hyderabad, Telangana, India
[2] Homi Bhabha Canc Hosp & Res Ctr, Visakhapatnam, Andhra Pradesh, India
[3] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA
[4] Osmania Univ, Dept Genet, Hyderabad, Telangana, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-4682
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4682
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The phosphoinositide 3-kinase (PI3K)/AKT signaling pathway as a therapeutic target for the treatment of human acute myeloid leukemia (AML)
    Martelli, Alberto M.
    Tabellini, Giovanna
    Bortul, Roberta
    Nyakern, Maria
    Tazzari, Pier Luigi
    Evangelisti, Camilla
    Cocco, Lucio
    CURRENT SIGNAL TRANSDUCTION THERAPY, 2007, 2 (03) : 246 - 256
  • [42] Targeting PI3K/AKT/mTOR network for treatment of leukemia
    Bertacchini, Jessika
    Heidari, Nazanin
    Mediani, Laura
    Capitani, Silvano
    Shahjahani, Mohammad
    Ahmadzadeh, Ahmad
    Saki, Najmaldin
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (12) : 2337 - 2347
  • [43] Targeting PI3K/AKT/mTOR network for treatment of leukemia
    Jessika Bertacchini
    Nazanin Heidari
    Laura Mediani
    Silvano Capitani
    Mohammad Shahjahani
    Ahmad Ahmadzadeh
    Najmaldin Saki
    Cellular and Molecular Life Sciences, 2015, 72 : 2337 - 2347
  • [44] Efficacy of the expanded treatment program with imatinib mesylate in 109 patients with chronic myeloid leukemia (CML)
    Vysotskaya, L.
    Golenkov, A.
    Trifonova, E.
    Chernykh, Y.
    Lutskaya, T.
    Inyutkina, N.
    Chukavina, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 532 - 532
  • [45] Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia
    StCharles, Meaghan
    Bollu, Vamsi K.
    Hornyak, Elizabeth
    Coombs, John
    Blanchette, Christopher M.
    DeAngelo, Daniel J.
    BLOOD, 2009, 114 (22) : 870 - 870
  • [46] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [47] The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
    Kawauchi, Kiyotaka
    Ogasawara, Toshie
    Yasuyama, Masako
    Otsuka, Kuniaki
    Yamada, Osamu
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (05) : 550 - 559
  • [48] Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
    Sarker, Debashis
    Reid, Alison H. M.
    Yap, Timothy A.
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4799 - 4805
  • [49] Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
    Park, Sophie
    Chapuis, Nicolas
    Tamburini, Jerome
    Bardet, Valerie
    Cornillet-Lefebvre, Pascale
    Willems, Lise
    Green, Alexa
    Mayeux, Patrick
    Lacombe, Catherine
    Bouscary, Didier
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05): : 819 - 828
  • [50] The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia
    Chen, Yu
    Wang, Tongtong
    Du, Jing
    Li, Yanchun
    Wang, Xin
    Zhou, Yi
    Yu, XingXing
    Fan, Weimin
    Zhu, Qiaojuan
    Tong, Xiangmin
    Wang, Ying
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 47 (03) : 981 - 993
12345